Lilly Seeks China Approval for Orforglipron Weight Loss Pill as $3 Billion Expansion Takes Shape

A daily pill moves closer to Chinese patients

Eli Lilly submitted its oral obesity and type 2 diabetes medicine orforglipron to China's National Medical Products Administration at the end of 2025, positioning a pill taken without food or water restrictions for a market already drawing heavy investment from makers of weight loss drugs.

Lilly Executive Vice President Patrik Jonsson said in June that a Chinese launch could come between late 2026 and early 2027. The company is preparing with a $3 billion investment over 10 years, including production capacity in Beijing and a $200 million collaboration with Chinese pharmaceutical services company Pharmaron.

China's regulator has not given an approval date, and Chinese pricing, insurance coverage and the final permitted uses remain undecided. For patients, those decisions will determine when the medicine becomes available, who can receive it and how much treatment costs.

The United States approved orforglipron, sold there as Foundayo, on April 1, 2026, for adults with obesity or overweight accompanied by medical problems related to weight. Lilly's U.S. approval announcement says treatment must accompany a diet with fewer calories and increased physical activity.

The strongest headline result comes from the ATTAIN-1 trial: participants taking the highest dose who remained on treatment lost an average of 12.4% of their starting weight over 72 weeks. A broader estimate that included treatment interruptions and discontinuation put average weight loss at 11.1%. Understanding both figures helps explain what the pill achieved and what patients may experience.

What makes orforglipron different?

Orforglipron belongs to the GLP-1 class of medicines. These medicines activate a receptor used by a natural hormone involved in appetite and blood sugar regulation. In simple terms, they help the body respond to food and can reduce the desire to eat.

Lilly's drug is a small molecule rather than a peptide. Peptides are chains of amino acids, the building blocks of proteins, and can be broken down in the digestive system. Orforglipron's different chemical structure allows it to be taken as a daily tablet without fasting or restrictions on water intake.

Oral semaglutide, including the Wegovy pill, uses a peptide structure and has more demanding administration instructions. The oral Wegovy regimen requires taking the tablet in the morning on an empty stomach, then waiting at least 30 minutes before eating, drinking or taking other oral medicines.

Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, described why dosing flexibility matters for people managing obesity:

People living with obesity need treatment options that meet them where they are – and for many, a once-daily pill that can be taken with no food or water restrictions can offer them greater flexibility in how they approach their treatment.

A tablet offers another choice for people reluctant to inject a medicine. It still requires a daily routine, a prescription and medical supervision. Lilly's instructions say tablets should be swallowed whole, and treatment should follow the schedule set by a healthcare professional.

What the weight loss figures mean

ATTAIN-1 followed 3,127 adults for 72 weeks. Participants had obesity, or overweight with at least one associated condition such as high blood pressure, abnormal blood lipids, obstructive sleep apnea or cardiovascular disease. They did not have diabetes.

The study randomly assigned participants to different doses of orforglipron or a placebo, a treatment without the active drug. Everyone also received guidance on healthy eating and physical activity. Neither participants nor investigators knew which treatment each person was receiving during the blinded trial.

Lilly reported two ways of estimating the highest dose's effect. The estimate assuming participants remained on treatment showed average weight loss of 27.3 pounds, or 12.4%, compared with 2.2 pounds, or 0.9%, with placebo. The broader treatment regimen estimate showed 25 pounds, or 11.1%, compared with 5.3 pounds, or 2.1%, with placebo.

The first estimate describes the expected effect with continued treatment under the study conditions. The second includes the effect of people stopping treatment or using other weight management treatments. Both are useful because staying on a medicine is part of the practical challenge of treating obesity.

For a person starting at 100 kilograms, 12.4% would equal 12.4 kilograms. Individual results varied: nearly four in 10 participants in the highest dose group lost more than 15% of their starting weight, according to the reported trial findings.

China participated in the clinical programme

Chinese participants took part in both major ATTAIN studies. ATTAIN-1 recruited across 10 locations, including China, India, Japan and South Korea. ATTAIN-2 enrolled more than 1,600 adults with obesity or overweight and type 2 diabetes, also including participants in China.

The two studies address different clinical populations. ATTAIN-1 measured weight management in adults without diabetes, while ATTAIN-2 examined adults who also had type 2 diabetes. That matters because the Chinese application seeks permission for both obesity treatment and diabetes treatment.

The wider development programme reportedly enrolled more than 10,000 participants, with Chinese participants included in six studies. That larger figure covers a broader research effort; ATTAIN-1 itself enrolled 3,127 people.

Lilly's April announcement described more than 4,500 participants across the two ATTAIN registration trials and said the company had submitted orforglipron for weight management and/or type 2 diabetes in more than 40 countries. The U.S. approval described in that announcement covers weight management.

Changes beyond the number on the scale

Participants in the ATTAIN programme also experienced reductions in waist circumference, non-HDL cholesterol, triglycerides and systolic blood pressure across the doses studied, according to Lilly. Non-HDL cholesterol measures cholesterol carried by particles associated with fatty deposits in arteries. Triglycerides are another type of fat in the blood.

Systolic blood pressure is the top number in a blood pressure reading. Together with waist size and blood fats, it helps doctors assess a person's cardiovascular health. These measures give a fuller picture of treatment than weight alone.

Chinese accounts of the trial findings also described reduced visceral fat, the fat stored around organs inside the abdomen. For someone receiving treatment, changes in weight, waist size, blood pressure and blood sugar may all form part of medical follow up.

How the approval effort has developed

Lilly's application, manufacturing plans and U.S. launch have progressed on separate tracks. The main milestones are:

• End of 2025: Lilly submitted its Chinese marketing application for orforglipron for obesity and type 2 diabetes.
• March 11, 2026: Lilly announced plans to invest $3 billion over 10 years in its Chinese supply chain, including local production partnerships.
• April 1, 2026: Lilly announced FDA approval of Foundayo for adult weight management in the United States.
• April 6, 2026: U.S. shipping through LillyDirect was scheduled to begin, with pharmacies and telehealth providers to follow.
• June 2026: Jonsson outlined a possible Chinese launch between late 2026 and early 2027.

Jonsson's launch window is a company expectation, with Chinese regulatory approval still required. Lilly has said it plans to introduce orforglipron in countries shortly after receiving the necessary permission.

Novo Nordisk is preparing a competing application. Chief Executive Mike Doustdar said in Beijing in June that the company planned to seek Chinese approval for its Wegovy weight loss pill "very soon." Oral semaglutide already has a diabetes indication in China, while the companies are competing to bring oral obesity treatments to patients.

Where Lilly's $3 billion will go

Lilly plans to expand existing incretin injection production in Suzhou and add capacity for oral solid medicines in Beijing. Incretin medicines act on hormone pathways involved in blood sugar control and appetite. The investment therefore covers both injections and tablets.

The Suzhou site, established in 1996, was already undergoing expansion following a $212 million investment announced in October 2024. The new programme combines work at Lilly's own facilities with manufacturing partnerships, beginning with the $200 million Pharmaron collaboration.

Huzur Devletsah, Lilly's vice president and general manager of China, explained the purpose of the Beijing investment:

The increased investment in Beijing signifies our continued commitment to improving our full-value-chain supply system in China to better meet the growing needs of Chinese patients.

The latest pledge brings Lilly's total investment in China to nearly $6 billion. Jonsson said there were no Chinese supply constraints for orforglipron and that Lilly planned to use existing partnerships with Alibaba and JD Health International for distribution.

Access will depend on more than supply

China already has a substantial market for GLP-1 medicines. Jefferies estimated that sales through Alibaba and JD.com reached about 1.4 billion yuan, or $207 million, in the first quarter of 2026. That figure covers GLP-1 treatments sold through those platforms rather than the entire Chinese market.

Health figures cited in Chinese coverage put adult overweight prevalence at 34.3% and obesity prevalence at 16.4%. Together, those figures equal 50.7%, slightly more than half of adults. The number of people eligible for a particular medicine will depend on its approved label and individual medical assessment.

U.S. prices provide a reference for Lilly's commercial approach. Its April announcement said eligible patients with commercial insurance could pay as little as $25 a month using a savings card, while payment without insurance started at $149 a month for the lowest dose. The company also expected eligible Medicare Part D patients to gain access for $50 a month as soon as July 1, 2026.

Those prices apply to specific U.S. arrangements. Chinese patients will face local pricing and coverage decisions. An oral medicine may fit some daily routines more easily, while affordability, side effects and the ability to continue treatment will also shape use.

A prescription medicine with serious warnings

Orforglipron is a prescription medicine, not a weight loss supplement. Common adverse effects listed by Lilly include nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain. Other listed effects include fatigue, headache, heartburn and hair loss.

The medicine carries a boxed warning concerning thyroid tumors, including thyroid cancer. Lilly's U.S. safety information says people with a personal or family history of medullary thyroid carcinoma must not take it. It is also prohibited for people with multiple endocrine neoplasia syndrome type 2, known as MEN 2, and those who have had a serious allergic reaction to the drug or its ingredients.

Other serious risks include pancreatitis, severe stomach problems, gallbladder problems and dehydration that can lead to kidney problems. Low blood sugar is a particular concern when the medicine is combined with insulin or a sulfonylurea. Patients should tell clinicians about planned surgery or procedures involving anesthesia because food or liquid can enter the lungs during such procedures.

Lilly's instructions also address pregnancy and contraception. The medicine may harm an unborn baby, breastfeeding is not recommended during treatment, and oral contraceptives may work less well. Healthcare professionals may recommend another contraceptive method for 30 days after treatment begins and for 30 days after each dose increase.

The U.S. safety information advises against combining Foundayo with other GLP-1 receptor agonists and says safety and effectiveness in children are unknown. A doctor's assessment should cover existing illnesses, other medicines and the practical demands of continuing treatment.

Key Points

• Lilly submitted orforglipron to China's regulator at the end of 2025 for obesity and type 2 diabetes.
• A Lilly executive outlined a possible Chinese launch between late 2026 and early 2027, subject to approval.
• The daily small molecule tablet can be taken without food or water restrictions.
• ATTAIN-1 reported 12.4% average weight loss with continued treatment at the highest dose and 11.1% under the broader treatment regimen estimate.
• Lilly plans a $3 billion investment over 10 years in China, including tablet production and a Pharmaron partnership.
• The medicine requires medical supervision and carries a boxed thyroid tumor warning and other serious safety precautions.